<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22352" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diffuse Toxic Goiter</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Gauri</given-names>
          </name>
          <aff>Sharda University,Greater Noida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Correa</surname>
            <given-names>Ricardo</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gauri Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ricardo Correa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22352.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Goiter is an anatomical enlargement of the thyroid gland. It can be related with thyroid dysfunction or have normal thyroid function. This activity review the evaluation, and treatment of diffuse toxic goiter and explains the role of the interprofessional team in evaluating and patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of diffuse toxic goiter medical conditions and emergencies.</p></list-item><list-item><p>Outline the appropriate evaluation of diffuse toxic goiter.</p></list-item><list-item><p>Review management options available for diffuse toxic goiter.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance the care of diffuse toxic goiter and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22352&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22352">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22352.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Goiter simply refers to the enlargement of the thyroid gland. It can be due to various causes with the dietary iodine deficiency being the most common cause worldwide. In the United States, however, Graves disease and Hashimoto disease are the most commonly seen in clinical practice. The goiters have been classified in different categories, as per morphology (described as nodular versus diffuse), functional status (that could be hyperthyroid, hypothyroid, or euthyroid), the presence of malignancy, etc. By definition, a diffuse toxic goiter refers to a diffusely&#x000a0;hyperplastic thyroid gland that is excessively overproducing the thyroid hormones. See <bold>Image.</bold>&#x000a0;Toxic&#x000a0;Nodular&#x000a0;Goiter.</p>
      </sec>
      <sec id="article-22352.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The following are potential commonly seen causes of a goiter development:</p>
        <list list-type="bullet">
          <list-item>
            <p>Iodine deficiency<xref ref-type="bibr" rid="article-22352.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Autoimmune disorders<xref ref-type="bibr" rid="article-22352.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Smoking</p>
          </list-item>
          <list-item>
            <p>Hereditary pattern<xref ref-type="bibr" rid="article-22352.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Medications, like for example lithium, iodides, interferon-alpha<xref ref-type="bibr" rid="article-22352.r4">[4]</xref>&#x000a0;among others</p>
          </list-item>
          <list-item>
            <p>Radiation therapy<xref ref-type="bibr" rid="article-22352.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Inflammation and infections&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22352.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The most common cause of diffuse toxic goiter is Graves disease. It is the most common cause of hyperthyroidism in the United States and worldwide affecting 1 in 200 people.</p>
        <p>It usually affects people between 30 and 50 years of age, but can occur in any age group. It is 7 to 10 times more common in females than in males (see <bold>Image.</bold> Goiter in a Female). A marked increase in familial incidence has also been observed.</p>
      </sec>
      <sec id="article-22352.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Diffuse toxic goiter consists of a diffusely enlarged, vascular gland with rubber-like consistency. Microscopically, the follicular cells are hypertrophic and hyperplastic with little colloid in them. Lymphocytes and plasma cells infiltrate into the gland and&#x000a0;can ultimately aggregate into lymphoid follicles.</p>
        <p>All cases of diffuse toxic goiter are not Graves disease and there may be various non-autoimmune causative processes although the majority of cases are autoimmune in nature. In Graves disease, antibodies are directed towards the thyroid-stimulating hormone receptor (TSHr) which is present on thyroid follicular cells. The chronic stimulation of these receptors results in the production of excess amounts of T3 and T4 hormones and causes the enlargement of the thyroid gland that eventually results in a goiter.<xref ref-type="bibr" rid="article-22352.r6">[6]</xref></p>
      </sec>
      <sec id="article-22352.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>This disease has the following histological characteristics:<xref ref-type="bibr" rid="article-22352.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse non-nodular enlargement of the gland with a smooth capsule and increased vascularity.</p>
          </list-item>
          <list-item>
            <p>Hyperplasia of both follicular and papillary cells with lymphocytic infiltration into the stroma of the thyroid gland</p>
          </list-item>
          <list-item>
            <p>Follicular cells can also be enlarged and, in extreme cases, have enlarged nuclei mimicking that of papillary thyroid carcinoma. In Graves disease, however, they tend to maintain their rounded shape and have minimal clearing.</p>
          </list-item>
        </list>
        <p>Due to the last point above, there have been controversies regarding the association between Graves disease and papillary thyroid carcinoma, and whether the coexistence of the two affects the prognosis. On systematic review of various studies, it has been seen that if a papillary carcinoma is discovered after surgical removal of the gland the prognosis is excellent, whereas when discovering a tumor in a patient with Graves disease, the local characteristics of the tumor (like the size, extent, margins, functionality, etc.) will most probably decide the final prognosis.<xref ref-type="bibr" rid="article-22352.r8">[8]</xref></p>
      </sec>
      <sec id="article-22352.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History </bold>
<xref ref-type="bibr" rid="article-22352.r9">[9]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients may&#x000a0;present with a history of one or more&#x000a0;consequences of a hyperthyroid state. These include weight loss, heat intolerance (with other heat-related symptoms like polydipsia, sweating), tremors, nervousness, anxiety, fatigue, palpitations, shortness of breath, frequent defecation or diarrhea, nausea, vomiting, etc.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients may also complain of an obvious neck swelling or sensation of a lump in the neck, globus, swallowing difficulty, orthopnea, etc.</p>
          </list-item>
          <list-item>
            <p>Patients with Graves disease may present with additional features like:</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Ophthalmopathy known as Graves orbitopathy (seen in 25% of patients) that includes proptosis, diplopia, periorbital edema, excessive lacrimation, etc.</p>
          </list-item>
          <list-item>
            <p>Thyroid dermatopathy (more rare, only seen in 4% of patients and usually concurrent with orbitopathy) that presents with slightly thickened pigmented skin, especially over the pretibial area.</p>
          </list-item>
          <list-item>
            <p>Abnormalities of the reproductive system, most frequently presenting as irregular menstruation</p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>The most commonly described findings in a patient with the diffuse toxic goiter on physical exam are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Constitutional: weight loss</p>
          </list-item>
          <list-item>
            <p>Head, eyes, ears, neck: neck swelling with occasional audible bruit, proptosis, lid lag, periorbital edema, exophthalmos</p>
          </list-item>
          <list-item>
            <p>Cardiovascular system: tachycardia, irregular heartbeat, systolic hypertension</p>
          </list-item>
          <list-item>
            <p>Neuromuscular: tremor of extremities, hyperreflexia, hyperactivity, muscle weakness</p>
          </list-item>
          <list-item>
            <p>Respiratory system: shortness of breath or tachypnea</p>
          </list-item>
          <list-item>
            <p>Skin and extremities: moist and warm skin, sweaty hands, pretibial myxedema</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22352.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The primary evaluation of the toxic diffuse goiter consists of a complete thyroid profile, including serum T3, T4, and TSH levels.</p>
        <list list-type="bullet">
          <list-item>
            <p>The serum TSH is the best screening test for evaluating thyroid hormone excess or deficiency.<xref ref-type="bibr" rid="article-22352.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>In the case of diffuse toxic goiter, the above tests usually result in low or marginally low normal TSH levels with elevated peripheral serum thyroid hormone levels.</p>
          </list-item>
          <list-item>
            <p>Based on preferences in accordance with population characteristics, socioeconomic reasons, and cultural backgrounds, the modalities of evaluation of the cause of thyrotoxicosis can either be radioactive iodide uptake or a combination of thyroid ultrasound with TSH-receptor antibodies.<xref ref-type="bibr" rid="article-22352.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>A high radioactive iodine uptake diffusely depicts Graves disease, as does an enlarged gland with positive TSH-receptor antibodies (TRAb).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22352.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment modalities for diffuse toxic goiter include:</p>
        <p><bold>Antithyroidthyroid Drugs (ATD)</bold><xref ref-type="bibr" rid="article-22352.r11">[11]</xref>&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>The antithyroid drug options are propylthiouracil, methimazole, and carbimazole.</p>
          </list-item>
          <list-item>
            <p>The American Thyroid Association (ATA) and American Association of Clinical Endocrinology (AACE) recommend methimazole as the preferred drug for Graves disease, except in patients with adverse reactions to the drug or women in the first trimester of pregnancy. It is preferred over propylthiouracil due to&#x000a0;better efficacy, longer half-life and duration of action, and the ease of using it as a once a day dosing.</p>
          </list-item>
          <list-item>
            <p>There are two different regimens to administer ATDs. The first is titration, where the dose of ATD is tapered to the lowest possible dose when the euthyroid state is achieved. The second regimen is based on block-and-replace method, where a high dose of ATD is given adjunct with thyroxine replacement to ultimately maintain a euthyroid state.<xref ref-type="bibr" rid="article-22352.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>A drawback of ATD therapy is the risk of recurrence, especially in the first year after stopping therapy. Studies reported a 50% to 55% risk of recurrence, with poor prognostic factors pointing to this direction incuding severe&#x000a0;hyperthyroidism, large goiter, high T3: T4 ratios, persistently suppressed TSH, and high baseline concentrations of TRAb.<xref ref-type="bibr" rid="article-22352.r13">[13]</xref><xref ref-type="bibr" rid="article-22352.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Rare but&#x000a0;major side effects of ATD therapy include agranulocytosis, hepatotoxicity, and vasculitis.</p>
          </list-item>
        </list>
        <p>
<bold>Radioactive Iodine Therapy (I-31, RAI)</bold>
<xref ref-type="bibr" rid="article-22352.r13">[13]</xref>
</p>
        <list list-type="order">
          <list-item>
            <p>RAI is the commonest modality to treat Graves disease in the United States and it is a very safe and effective form&#x000a0;of treatment.</p>
          </list-item>
          <list-item>
            <p>The absolute contraindications of this therapy include pregnancy, breastfeeding, and severe uncontrolled thyrotoxicosis.</p>
          </list-item>
          <list-item>
            <p>It can be administered in liquid or capsule forms, and fixed-dose therapy is as effective as calculated dose therapy based on the volume of the gland, iodine uptake, etc.</p>
          </list-item>
          <list-item>
            <p>Patients must discontinue all iodine-containing medication and be on iodine restricted diet to ensure effective uptake of RAI.</p>
          </list-item>
          <list-item>
            <p>ATD therapy needs to be discontinued preferably a week before the use of RAI and it can be resumed a few days after administering RAI, if needed.</p>
          </list-item>
          <list-item>
            <p>Potential side effects include the risk of developing hypothyroidism, and in rare occasions transient radiation-induced hyperthyroidism or worsening of thyroid-associated ophthalmopathy (TAO).</p>
          </list-item>
          <list-item>
            <p>While hypothyroidism is actively screened at subsequent follow-ups, prednisone can be used to prevent the progression of mild TAO.</p>
          </list-item>
          <list-item>
            <p>Patients have to be counseled about lifelong follow-up for either disease recurrence or for the development of hypothyroidism and they will benefit from prompt treatment if diagnosed with either abnormality.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Surgery</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Thyroidectomy is the most successful form of therapy for a diffuse toxic goiter, with total thyroidectomy being more successful than sub-total thyroidectomy with equivalent side effects.</p>
          </list-item>
          <list-item>
            <p>Due to the side effects associated with the use of general anesthesia, recurrent laryngeal nerve palsy, vascular complications, and hypothyroidism, surgical intervention is usually the last line of treatment.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It is preferred in patients who are unable to tolerate antithyroid medications or RAI treatment, or in patients with compressive symptoms due to a bigger size of the goiter.<xref ref-type="bibr" rid="article-22352.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22352.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Although diagnosed through the various forms of evaluation, as described in details above, the differential diagnosis of diffuse toxic goiter includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Thyrotoxicosis factitia with over prescription or consumption of thyroid&#x000a0;hormones</p>
          </list-item>
          <list-item>
            <p>Subacute or acute thyroiditis</p>
          </list-item>
          <list-item>
            <p>Multinodular goiter</p>
          </list-item>
          <list-item>
            <p>TSH secreting pituitary adenoma</p>
          </list-item>
          <list-item>
            <p>Iatrogenic iodine supplementation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22352.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with diffuse toxic goiter, especially due to Graves disease, are expected to&#x000a0;become hypothyroid during the natural course of their disease regardless of treatment. Prolonged thyrotoxicosis may cause ventricular thickening and, therefore, an increased risk of cardiac morbidity and mortality.</p>
        <p>Treatment with RAI is done with the aim of permanent hypothyroidism, thus making the patient dependant on life long thyroid hormone supplementation. ATDs have an average remission rate of 50% but an excellent prognosis after 4 years, devoid of relapse.<xref ref-type="bibr" rid="article-22352.r16">[16]</xref></p>
      </sec>
      <sec id="article-22352.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Hyperthyroidism, or thyroid storm due to prolonged untreated excess of thyroid hormone</p>
          </list-item>
          <list-item>
            <p>Cardiac arrhythmias and congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Rare liver pathology including fibrosis<xref ref-type="bibr" rid="article-22352.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Dermatopathy, mostly associated with Graves disease</p>
          </list-item>
          <list-item>
            <p>Graves ophthalmopathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22352.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients with diffuse goiters are advised to be evaluated by endocrinologists to undergo more detailed testing. Team work between primary care physicians, radiologists, surgeons and endocrine specialists should be coordinated for achieving better outcomes. Pharmacists should also counsel the patients on potential side effects of the medications used for their treatment, so they can be aware of the findings and report them to their doctors in a timely manner. Treatment approach steps should be discussed in advance and the patients should be provided with details of the expected advantages versus disadvantages of the different treatment choices. On several occasions, the physicians involved in the care of those patients will need to communicate closely to prepare the patients for the next steps to guarantee better compliance and results.</p>
      </sec>
      <sec id="article-22352.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Diffuse toxic goiter may present with the usual hypermetabolic (like for example the heat intolerance, sweating, weight loss, etc.) and adrenergic symptoms (in particular the palpitations, tremors, emotional lability, etc.) of hyperthyroidism, along with the swelling of the goiter. On the other hand the elderly patients may not present with adrenergic symptoms, but rather with apathy, and atrial fibrillation, which might also be represents symptoms of depression, malignancy, or cardiac abnormalities.&#x000a0;</p>
      </sec>
      <sec id="article-22352.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Although a lot of the cases of diffuse goiter remain asymptomatic, patients who notice any enlarged thyroid should be referred for specialty evaluation to investigate the function of the gland at the same time that the anatomy is looked at in more details. Blood tests focusing on the thyroid hormone levels and a neck ultrasound are the easiest starting points, and depending on their findings, further testing can be pursued as explained earlier.</p>
      </sec>
      <sec id="article-22352.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing diffuse toxic goiter is an amalgamation of clinical signs and investigations. Evaluating radiological and blood testings are important in reaching a conclusion to the underlying cause of the disease. Once diagnosed, it is the physician's responsibility to help the patient pick the best treatment option based on their profile, and with a thorough understanding of potential side effects. Women need to be especially careful and well informed as while being pregnant or breastfeeding they may require to change their form of therapy. Since this condition can also lead to cosmetic concerns (like the bulging of the neck or eventually the eyes,etc.) all physicians need to be sensitive and perceptive to them and counsel the patients about treatment options available, along with having a realistic approach to the treatment response.</p>
      </sec>
      <sec id="article-22352.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22352&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22352">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/diffuse-toxic-goiter/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22352">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22352/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22352">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22352.s18">
        <fig id="article-22352.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Toxic Nodular Goiter Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="toxicnodular" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22352.s19">
        <fig id="article-22352.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Goiter in a Female Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="goiter" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22352.s20">
        <title>References</title>
        <ref id="article-22352.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimmermann</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Boelaert</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Iodine deficiency and thyroid disorders.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>286</fpage>
            <page-range>286-95</page-range>
            <pub-id pub-id-type="pmid">25591468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune thyroid disorders-An update.</article-title>
            <source>Indian J Clin Biochem</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-17</page-range>
            <pub-id pub-id-type="pmid">23105486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knobel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>357</fpage>
            <page-range>357-73</page-range>
            <pub-id pub-id-type="pmid">26392367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>How medications affect thyroid function.</article-title>
            <source>West J Med</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>172</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-6</page-range>
            <pub-id pub-id-type="pmid">10693372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jereczek-Fossa</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Alterio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jassem</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibelli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tradati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Orecchia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy-induced thyroid disorders.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-84</page-range>
            <pub-id pub-id-type="pmid">15145511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prabhakar</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.</article-title>
            <source>Endocr Rev</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>802</fpage>
            <page-range>802-35</page-range>
            <pub-id pub-id-type="pmid">14671007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LiVolsi</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Baloch</surname>
                <given-names>ZW</given-names>
              </name>
            </person-group>
            <article-title>The Pathology of Hyperthyroidism.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>737</fpage>
            <pub-id pub-id-type="pmid">30559722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oertli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harder</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oberholzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Staub</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>[Hyperthyroidism and thyroid carcinoma--coincidence or association?].</article-title>
            <source>Schweiz Med Wochenschr</source>
            <year>1998</year>
            <month>Nov</month>
            <day>28</day>
            <volume>128</volume>
            <issue>48</issue>
            <fpage>1910</fpage>
            <page-range>1910-4</page-range>
            <pub-id pub-id-type="pmid">9879620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Leo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Hyperthyroidism.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Aug</month>
            <day>27</day>
            <volume>388</volume>
            <issue>10047</issue>
            <fpage>906</fpage>
            <page-range>906-918</page-range>
            <pub-id pub-id-type="pmid">27038492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baskin</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Cobin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Duick</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Gharib</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guttler</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>RL</given-names>
              </name>
              <collab>American Association of Clinical Endocrinologists</collab>
            </person-group>
            <article-title>American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism.</article-title>
            <source>Endocr Pract</source>
            <year>2002</year>
            <season>Nov-Dec</season>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-69</page-range>
            <pub-id pub-id-type="pmid">15260011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Antithyroid Drug Treatment in Graves' Disease.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>491</fpage>
            <page-range>491-499</page-range>
            <pub-id pub-id-type="pmid">34130446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allannic</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fauchet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orgiazzi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Madec</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Genetet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lorcy</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Le Guerrier</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Delambre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Derennes</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>675</fpage>
            <page-range>675-9</page-range>
            <pub-id pub-id-type="pmid">1689737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avenell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McGeoch</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Bevan</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Antithyroid drug regimen for treating Graves' hyperthyroidism.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2010</year>
            <month>Jan</month>
            <day>20</day>
            <volume>2010</volume>
            <issue>1</issue>
            <fpage>CD003420</fpage>
            <pub-id pub-id-type="pmid">20091544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azizi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abdi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amouzegar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Habibi Moeini</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Long-term thionamide antithyroid treatment of Graves' disease.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>101631</fpage>
            <pub-id pub-id-type="pmid">35440398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girgis</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in graves' disease.</article-title>
            <source>Ther Adv Endocrinol Metab</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-44</page-range>
            <pub-id pub-id-type="pmid">23148179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Graves' Disease: Can It Be Cured?</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-38</page-range>
            <pub-id pub-id-type="pmid">30912336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22352.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavruk</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Dudiy</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Skrypnyk</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Mishchuk</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Vytvytskiy</surname>
                <given-names>ZY</given-names>
              </name>
            </person-group>
            <article-title>Clinical-laboratory and ultrasound parallels of changes in the liver and thyroid gland in diffuse toxic goiter.</article-title>
            <source>J Med Life</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-88</page-range>
            <pub-id pub-id-type="pmid">35186140</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
